• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

接种 mRNA SARS-CoV-2 疫苗后，无论既往感染与否，抗体水平的持久性。

Durability of Antibody Levels After Vaccination With mRNA SARS-CoV-2 Vaccine in Individuals With or Without Prior Infection.

机构信息

Johns Hopkins University School of Medicine, Baltimore, Maryland.

Johns Hopkins School of Public Health, Baltimore, Maryland.

出版信息

JAMA. 2021 Dec 28;326(24):2524-2526. doi: 10.1001/jama.2021.19996.

DOI:10.1001/jama.2021.19996
PMID:34724529
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8561429/
Abstract

This study examines antibody durability in individuals who received an mRNA SARS-CoV-2 vaccine with prior SARS-CoV-2 infection vs those without infection.

摘要

本研究考察了既往感染 SARS-CoV-2 后又接种了 mRNA SARS-CoV-2 疫苗的个体与未感染的个体的抗体持久性。

相似文献

1
Durability of Antibody Levels After Vaccination With mRNA SARS-CoV-2 Vaccine in Individuals With or Without Prior Infection.接种 mRNA SARS-CoV-2 疫苗后，无论既往感染与否，抗体水平的持久性。
JAMA. 2021 Dec 28;326(24):2524-2526. doi: 10.1001/jama.2021.19996.
2
Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months.维持性透析患者接种 SARS-CoV-2 疫苗后 6 个月的血清学反应。
Clin J Am Soc Nephrol. 2022 Mar;17(3):403-413. doi: 10.2215/CJN.12250921. Epub 2022 Feb 10.
3
Association of Vaccine Type and Prior SARS-CoV-2 Infection With Symptoms and Antibody Measurements Following Vaccination Among Health Care Workers.疫苗类型和既往 SARS-CoV-2 感染与医护人员接种疫苗后症状和抗体测量的关联。
JAMA Intern Med. 2021 Dec 1;181(12):1660-1662. doi: 10.1001/jamainternmed.2021.4580.
4
Antibody response to SARS-CoV-2 vaccination is extremely vivacious in subjects with previous SARS-CoV-2 infection.既往感染过 SARS-CoV-2 的受试者对 SARS-CoV-2 疫苗接种的抗体反应极为活跃。
J Med Virol. 2021 Jul;93(7):4612-4615. doi: 10.1002/jmv.26982. Epub 2021 Apr 8.
5
The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity.mRNA-1273 疫苗诱导对 SARS-CoV-2 的交叉变体抗体反应，具有预先存在免疫个体和无预先存在免疫个体的不同特征。
Front Immunol. 2021 Sep 3;12:737083. doi: 10.3389/fimmu.2021.737083. eCollection 2021.
6
Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel.以色列卫生保健工作者中，第三剂 BNT162b2 疫苗接种与 SARS-CoV-2 感染发生率的关联。
JAMA. 2022 Jan 25;327(4):341-349. doi: 10.1001/jama.2021.23641.
7
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.SARS-CoV-2 mRNA-1273疫苗接种后反应的持久性。
N Engl J Med. 2021 Jan 7;384(1):80-82. doi: 10.1056/NEJMc2032195. Epub 2020 Dec 3.
8
Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2.先前感染过 SARS-CoV-2 的个体对 BNT162b2 mRNA 疫苗的抗体反应。
Nat Med. 2021 Jun;27(6):981-984. doi: 10.1038/s41591-021-01325-6. Epub 2021 Apr 1.
9
Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.一种雾化型腺病毒 5 型载体新冠疫苗（Ad5-nCoV）在成年人中的安全性、耐受性和免疫原性：一项开放标签、随机 1 期临床试验的初步报告。
Lancet Infect Dis. 2021 Dec;21(12):1654-1664. doi: 10.1016/S1473-3099(21)00396-0. Epub 2021 Jul 26.
10
SARS-CoV-2 vaccines: anamnestic response in previously infected recipients.严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）疫苗：既往感染者的回忆性反应。
Cell Res. 2021 Aug;31(8):827-828. doi: 10.1038/s41422-021-00516-7.

引用本文的文献

1
Prevalence of SARS-CoV-2 infection and immunity in a New York county in 2022 reveals frequent asymptomatic or undiagnosed infections.2022年纽约某县新冠病毒2型感染及免疫情况调查显示，无症状或未被诊断出的感染情况很常见。
PLoS One. 2025 May 28;20(5):e0323659. doi: 10.1371/journal.pone.0323659. eCollection 2025.
2
SARS-Cov-2 vaccination strategies in hospitalized recovered COVID-19 patients: a randomized clinical trial (VATICO Trial).住院康复的新冠病毒肺炎患者的严重急性呼吸综合征冠状病毒2疫苗接种策略：一项随机临床试验（VATICO试验）
Sci Rep. 2025 Mar 22;15(1):9882. doi: 10.1038/s41598-025-92742-x.
3
Safety, immunogenicity, and breakthrough infections during 1-year follow-up after COVISHIELD™ vaccination among healthcare workers in a teaching institute in North India: A prospective longitudinal study.印度北部一所教学机构的医护人员接种COVISHIELD™疫苗后1年随访期间的安全性、免疫原性和突破性感染：一项前瞻性纵向研究。
J Family Med Prim Care. 2025 Feb;14(2):655-661. doi: 10.4103/jfmpc.jfmpc_935_24. Epub 2025 Feb 21.
4
Durability of Adaptive Immunity in Immunocompetent and Immunocompromised Patients Across Different Respiratory Viruses: RSV, Influenza, and SARS-CoV-2.免疫功能正常和免疫功能低下患者针对不同呼吸道病毒（呼吸道合胞病毒、流感病毒和严重急性呼吸综合征冠状病毒2）的适应性免疫持久性
Vaccines (Basel). 2024 Dec 22;12(12):1444. doi: 10.3390/vaccines12121444.
5
Optimal Annual COVID-19 Vaccine Boosting Dates Following Previous Booster Vaccination or Breakthrough Infection.先前接种加强针疫苗或突破性感染后的最佳年度新冠病毒疫苗加强接种日期
Clin Infect Dis. 2025 Feb 24;80(2):316-322. doi: 10.1093/cid/ciae559.
6
The immune response to Covid-19 mRNA vaccination among Lymphoma patients receiving anti-CD20 treatment.接受抗 CD20 治疗的淋巴瘤患者对 Covid-19 mRNA 疫苗接种的免疫反应。
Front Immunol. 2024 Sep 4;15:1433442. doi: 10.3389/fimmu.2024.1433442. eCollection 2024.
7
Messenger RNA Vaccine Technology: Success for SARS-CoV-2 and Prospects for an HIV-1 Vaccine.信使 RNA 疫苗技术：SARS-CoV-2 的成功及 HIV-1 疫苗的前景。
Top Antivir Med. 2024 Apr 18;32(2):420-430.
8
The impact of previous SARS-CoV-2 infection on post-vaccine adverse events in individuals vaccinated with TURKOVAC or CoronaVac -inactivated COVID-19 vaccines.既往 SARS-CoV-2 感染对 TURKOVAC 或科兴新冠病毒灭活疫苗接种者疫苗后不良事件的影响。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2346388. doi: 10.1080/21645515.2024.2346388. Epub 2024 Jun 26.
9
COVID-19 Vaccine Side Effects and Long-Term Neutralizing Antibody Response : A Prospective Cohort Study.COVID-19 疫苗的副作用和长期中和抗体反应：一项前瞻性队列研究。
Ann Intern Med. 2024 Jul;177(7):892-900. doi: 10.7326/M23-2956. Epub 2024 Jun 11.
10
High Concentration of Anti-SARS-CoV-2 Antibodies 2 Years after COVID-19 Vaccination Stems Not Only from Boosters but Also from Widespread, Often Unrecognized, Contact with the Virus.新冠病毒疫苗接种两年后出现的高浓度抗SARS-CoV-2抗体不仅源于加强针，还源于广泛的、通常未被识别的与病毒的接触。
Vaccines (Basel). 2024 Apr 28;12(5):471. doi: 10.3390/vaccines12050471.

本文引用的文献

1
Extended interval BNT162b2 vaccination enhances peak antibody generation.延长间隔接种BNT162b2疫苗可增强抗体峰值生成。
NPJ Vaccines. 2022 Jan 27;7(1):14. doi: 10.1038/s41541-022-00432-w.
2
High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape.SARS-CoV-2 多克隆中和抗体逃逸的高遗传屏障。
Nature. 2021 Dec;600(7889):512-516. doi: 10.1038/s41586-021-04005-0. Epub 2021 Sep 20.
3
Association of Vaccine Type and Prior SARS-CoV-2 Infection With Symptoms and Antibody Measurements Following Vaccination Among Health Care Workers.疫苗类型和既往 SARS-CoV-2 感染与医护人员接种疫苗后症状和抗体测量的关联。
JAMA Intern Med. 2021 Dec 1;181(12):1660-1662. doi: 10.1001/jamainternmed.2021.4580.
4
Covid-19 Breakthrough Infections in Vaccinated Health Care Workers.新冠疫苗突破性感染在已接种疫苗的医护人员中发生。
N Engl J Med. 2021 Oct 14;385(16):1474-1484. doi: 10.1056/NEJMoa2109072. Epub 2021 Jul 28.
5
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.中和抗体水平高度预测对有症状的 SARS-CoV-2 感染的免疫保护作用。
Nat Med. 2021 Jul;27(7):1205-1211. doi: 10.1038/s41591-021-01377-8. Epub 2021 May 17.
6
Clinical Validity of Serum Antibodies to SARS-CoV-2 : A Case-Control Study.血清抗 SARS-CoV-2 抗体的临床有效性：一项病例对照研究。
Ann Intern Med. 2020 Oct 20;173(8):614-622. doi: 10.7326/M20-2889. Epub 2020 Jul 6.